1. Home
  2. PONO vs MDWD Comparison

PONO vs MDWD Comparison

Compare PONO & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PONO

Pono Capital Four Inc. Class A Ordinary Shares

N/A

Current Price

$10.04

Market Cap

174.2M

Sector

Finance

ML Signal

N/A

Logo MediWound Ltd.

MDWD

MediWound Ltd.

SELL

Current Price

$11.95

Market Cap

162.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PONO
MDWD
Founded
2026
2000
Country
Cayman Islands
Israel
Employees
N/A
N/A
Industry
Blank Checks
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
174.2M
162.2M
IPO Year
2026
2013

Fundamental Metrics

Financial Performance
Metric
PONO
MDWD
Price
$10.04
$11.95
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $30.67
AVG Volume (30 Days)
62.0K
★ 63.2K
Earning Date
11-12-2026
11-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$39.60
Revenue Next Year
N/A
$34.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$9.95
$11.87
52 Week High
$10.09
$20.03

Technical Indicators

Market Signals
Indicator
PONO
MDWD
Relative Strength Index (RSI) 61.16 32.52
Support Level $10.02 N/A
Resistance Level $10.09 $14.06
Average True Range (ATR) 0.01 0.42
MACD 0.00 -0.15
Stochastic Oscillator 37.50 3.69

Price Performance

Historical Comparison
PONO
MDWD

About PONO Pono Capital Four Inc. Class A Ordinary Shares

Pono Capital Four Inc is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: